Why buprenorphine prescribing still lags after the X-waiver repeal
The repeal of the “X-waiver” in the Consolidated Appropriations Act of 2023 was widely celebrated as a long-overdue step toward expanding access to buprenorphine for opioid use disorder (OUD). By removing the requirement for supplemental training and a special DEA designation, policymakers hoped to normalize treatment and reduce barriers for clinicians.
Yet nearly two years after, buprenorphine prescribing remains inconsistent across the country. Only one in four Americans …
Why buprenorphine prescribing still lags after the X-waiver repeal
